» Articles » PMID: 37227584

Curcumol β-cyclodextrin Inclusion Complex Enhances Radiosensitivity of Esophageal Cancer Under Hypoxic and Normoxic Condition

Overview
Journal Jpn J Radiol
Publisher Springer
Specialty Radiology
Date 2023 May 25
PMID 37227584
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Radiotherapy is an indispensable treatment for esophageal cancer (EC), but radioresistance is not uncommon. Curcumol, as an active extract from traditional Chinese medicines, has been reported to have antitumor activity in various types of human tumor cells. However, its reversal of radioresistance has been rarely reported.

Materials And Methods: In the present study, curcumol was prepared as an inclusion complex with β-cyclodextrin. EC cell lines were treated with radiation and curcumol β-cyclodextrin inclusion complex (CβC), and the effect of radiosensitization of CβC was investigated in vitro and in vivo. The in vitro experiments included cell proliferation assay, clonogenic survival assay, apoptosis assay, cell cycle assay, and western blot assay.

Results: The in vitro data revealed that CβC and irradiation synergistically inhibited the proliferation, reduced the colony formation, promoted the apoptosis, increased the G2/M phase, inhibited DNA damage repair, and reversed the hypoxia-mediated radioresistance of EC cells to a greater extent than did CβC alone or irradiation alone. The sensitization enhancement ratios (SERs) were 1.39 for TE-1 and 1.48 for ECA109 under hypoxia. The SERs were 1.25 for TE-1 and 1.32 for ECA109 under normoxia. The in vivo data demonstrated that the combination of CβC and irradiation could inhibit tumor growth to the greatest extent compared with either monotherapy alone. The enhancement factor was 2.45.

Conclusion: This study demonstrated that CβC could enhance radiosensitivity of EC cells under hypoxic and normoxic condition. Thus, CβC can be used as an effective radiosensitizer for EC.

Citing Articles

Role, mechanisms and effects of in anti‑breast cancer (Review).

Jiang S, Li C, Liu D, Zeng F, Wei W, He T Oncol Lett. 2025; 29(4):166.

PMID: 39963320 PMC: 11831725. DOI: 10.3892/ol.2025.14912.


APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.

Michaeli O, Luz I, Vatarescu M, Manko T, Weizman N, Korotinsky Y Cell Death Dis. 2024; 15(6):426.

PMID: 38890278 PMC: 11189442. DOI: 10.1038/s41419-024-06830-3.


Ozone enhances the efficacy of radiation therapy in esophageal cancer.

Guo J, Guo J, Cheng B, Gong M, Sun X, Zhang H J Radiat Res. 2024; 65(4):467-473.

PMID: 38842109 PMC: 11262864. DOI: 10.1093/jrr/rrae041.


Association between interstitial lung abnormality and mortality in patients with esophageal cancer.

Hata A, Yanagawa M, Miyata T, Hiraoka Y, Shirae M, Ninomiya K Jpn J Radiol. 2024; 42(8):841-851.

PMID: 38658500 PMC: 11286667. DOI: 10.1007/s11604-024-01563-x.


Curcumol: a review of its pharmacology, pharmacokinetics, drug delivery systems, structure-activity relationships, and potential applications.

Zhai S, Wang R, Wang J, Xu X, Niu L, Guo M Inflammopharmacology. 2024; 32(3):1659-1704.

PMID: 38520574 DOI: 10.1007/s10787-024-01447-6.


References
1.
Belozerov V, Van Meir E . Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs. 2005; 16(9):901-9. DOI: 10.1097/01.cad.0000180116.85912.69. View

2.
Zundel W, Schindler C, Koong A, Kaper F, Chen E, Gottschalk A . Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; 14(4):391-6. PMC: 316386. View

3.
Pan S, Sun Y, Sui D, Yang T, Fu S, Wang J . Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma. Biomed Pharmacother. 2018; 102:567-574. DOI: 10.1016/j.biopha.2018.03.109. View

4.
Schwarz D, Engelke A, Wenz G . Solubilizing steroidal drugs by β-cyclodextrin derivatives. Int J Pharm. 2017; 531(2):559-567. DOI: 10.1016/j.ijpharm.2017.07.046. View

5.
Duzgun Z, Eroglu Z, Biray Avci C . Role of mTOR in glioblastoma. Gene. 2015; 575(2 Pt 1):187-90. DOI: 10.1016/j.gene.2015.08.060. View